Abstract
The loss of bone and destruction of bone microstructure due to aging in senile osteoporosis (SOP) significantly impair the health and quality of life of the elderly. The pathogenesis of SOP is primarily related to osteogenic deficiency, attenuation of osteoblast function, insufficient bone formation, and eventual bone loss. While METTL1 is the major reported methyltransferase to catalyze RNA 7-methylguanosine (m7G) methylation, regulating mRNA transcription, miRNA biosynthesis, biological function, tRNA stability, RNA intracellular processing, and maturation, its role in the pathogenesis of SOP and osteogenic differentiation of BMSCs has not been studied. In this research, we found a significant decrease in METTL1 in BMSCs from SOP patients. Deletion of METTL1 significantly inhibited m7G modification of Runx2, impeding osteogenic differentiation of BMSCs in vitro and inducing SOP in vivo. We further developed bone-targeted lipid nanoparticles containing the m7G methylated Runx2 mRNA (ZA-m7G Runx2 mRNA-LNPs), which significantly promoted bone repair and formation in the bone defect mouse model as well as the SOP mouse. This study provides new basic theoretical theory and treatment strategies for the prevention and treatment of SOP by revealing a critical m7G RNA modification mechanism of osteogenic differentiation disorders of BMSCs in the pathogenesis of SOP.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
